1	Bradycardia-induced	Bradycardia-induced	B-NP	JJ	O	3	NMOD	17	induced
2	coronary	coronary	I-NP	JJ	O	3	NMOD	0
3	angiogenesis	angiogenesis	I-NP	NN	O	4	SUB	3	angiogenesis
4	is	be	B-VP	VBZ	O	0	ROOT	0
5	dependent	dependent	B-ADJP	JJ	O	4	PRD	17	dependent
6	on	on	B-PP	IN	O	5	AMOD	0
7	vascular	vascular	B-NP	JJ	B-protein	10	NMOD	0
8	endothelial	endothelial	I-NP	JJ	I-protein	10	NMOD	0
9	growth	growth	I-NP	NN	I-protein	10	NMOD	0
10	factor	factor	I-NP	NN	I-protein	6	PMOD	0
11	.	.	O	.	O	4	P	0

1	A	A	B-NP	DT	O	4	NMOD	0
2	marked	marked	I-NP	JJ	O	4	NMOD	0
3	coronary	coronary	I-NP	JJ	O	4	NMOD	0
4	angiogenesis	angiogenesis	I-NP	NN	O	5	SUB	3	angiogenesis
5	is	be	B-VP	VBZ	O	0	ROOT	0
6	known	know	I-VP	VBN	O	5	VC	0
7	to	to	I-VP	TO	O	8	VMOD	0
8	occur	occur	I-VP	VB	O	6	VMOD	0
9	with	with	B-PP	IN	O	8	VMOD	0
10	chronic	chronic	B-NP	JJ	O	11	NMOD	0
11	bradycardia	bradycardia	I-NP	NN	O	9	PMOD	0
12	.	.	O	.	O	5	P	0

1	We	We	B-NP	PRP	O	2	SUB	0
2	tested	test	B-VP	VBD	O	0	ROOT	0
3	the	the	B-NP	DT	O	4	NMOD	0
4	hypothesis	hypothesis	I-NP	NN	O	2	OBJ	0
5	that	that	B-SBAR	IN	O	4	NMOD	0
6	vascular	vascular	B-NP	JJ	B-protein	9	NMOD	0
7	endothelial	endothelial	I-NP	JJ	I-protein	9	NMOD	0
8	growth	growth	I-NP	NN	I-protein	9	NMOD	0
9	factor	factor	I-NP	NN	I-protein	17	NMOD	0
10	(	(	O	(	O	12	DEP	0
11	VEGF	VEGF	B-NP	NN	B-protein	12	DEP	0
12	)	)	O	)	O	9	NMOD	0
13	,	,	O	,	O	17	P	0
14	an	an	B-NP	DT	O	17	NMOD	0
15	endothelial	endothelial	I-NP	JJ	B-protein	17	NMOD	0
16	cell	cell	I-NP	NN	I-protein	17	NMOD	0
17	mitogen	mitogen	I-NP	NN	I-protein	21	NMOD	0
18	and	and	O	CC	O	21	NMOD	0
19	a	a	B-NP	DT	O	21	NMOD	0
20	major	major	I-NP	JJ	O	21	NMOD	0
21	regulator	regulator	I-NP	NN	O	25	SUB	0
22	of	of	B-PP	IN	O	21	NMOD	0
23	angiogenesis	angiogenesis	B-NP	NN	O	22	PMOD	3	angiogenesis
24	,	,	O	,	O	21	P	0
25	is	be	B-VP	VBZ	O	5	SBAR	0
26	upregulated	upregulate	I-VP	VBN	O	25	VC	17	upregulated
27	in	in	B-PP	IN	O	26	VMOD	0
28	response	response	B-NP	NN	O	27	PMOD	0
29	to	to	B-PP	TO	O	28	NMOD	0
30	low	low	B-NP	JJ	O	32	NMOD	0
31	heart	heart	I-NP	NN	O	32	NMOD	0
32	rate	rate	I-NP	NN	O	37	NMOD	0
33	and	and	O	CC	O	37	NMOD	0
34	consequential	consequential	B-NP	JJ	O	37	NMOD	0
35	increased	increase	I-NP	VBN	O	37	NMOD	0
36	stroke	stroke	I-NP	NN	O	37	NMOD	0
37	volume	volume	I-NP	NN	O	29	PMOD	0
38	.	.	O	.	O	2	P	0

1	Bradycardia	Bradycardia	B-NP	NNP	O	2	SUB	0
2	was	be	B-VP	VBD	O	0	ROOT	0
3	induced	induce	I-VP	VBN	O	2	VC	0
4	in	in	B-PP	IN	O	3	VMOD	0
5	rats	rat	B-NP	NNS	O	4	PMOD	0
6	by	by	B-PP	IN	O	3	VMOD	0
7	administering	administer	B-VP	VBG	O	6	PMOD	19	administering
8	the	the	B-NP	DT	O	11	NMOD	0
9	bradycardic	bradycardic	I-NP	JJ	O	11	NMOD	0
10	drug	drug	I-NP	NN	O	11	NMOD	0
11	alinidine	alinidine	I-NP	NN	O	7	OBJ	0
12	(	(	O	(	O	17	DEP	0
13	3	3	B-NP	CD	O	16	NMOD	0
14	mg/kg	mg/kg	I-NP	NN	O	16	NMOD	0
15	body	body	I-NP	NN	O	16	NMOD	0
16	weight	weight	I-NP	NN	O	17	DEP	0
17	)	)	O	)	O	11	NMOD	0
18	twice	twice	B-ADVP	RB	O	3	VMOD	0
19	daily	daily	I-ADVP	RB	O	18	AMOD	0
20	.	.	O	.	O	2	P	0

1	Heart	Heart	B-NP	NN	O	2	NMOD	0
2	rate	rate	I-NP	NN	O	3	SUB	0
3	decreased	decrease	B-VP	VBD	O	0	ROOT	0
4	by	by	B-PP	IN	O	3	VMOD	0
5	32	32	B-NP	CD	O	6	NMOD	0
6	%	%	I-NP	NN	O	4	PMOD	0
7	for	for	B-PP	IN	O	3	VMOD	0
8	20	20	B-NP	CD	O	10	AMOD	0
9	to	to	I-NP	TO	O	10	AMOD	0
10	40	40	I-NP	CD	O	11	NMOD	0
11	minutes	minute	I-NP	NNS	O	7	PMOD	0
12	after	after	B-PP	IN	O	3	VMOD	0
13	injection	injection	B-NP	NN	O	12	PMOD	0
14	and	and	O	CC	O	3	VMOD	0
15	was	be	B-VP	VBD	O	3	VMOD	0
16	chronically	chronically	I-VP	RB	O	15	VMOD	0
17	reduced	reduce	I-VP	VBN	O	15	VC	0
18	by	by	B-PP	IN	O	17	VMOD	0
19	10	10	B-NP	CD	O	20	NMOD	0
20	%	%	I-NP	NN	O	18	PMOD	0
21	,	,	O	,	O	3	P	0
22	14	14	B-NP	CD	O	23	NMOD	0
23	%	%	I-NP	NN	O	27	NMOD	0
24	,	,	O	,	O	27	P	0
25	and	and	O	CC	O	27	NMOD	0
26	18.5	18.5	B-NP	CD	O	27	NMOD	0
27	%	%	I-NP	NN	O	3	OBJ	0
28	after	after	B-PP	IN	O	27	NMOD	0
29	1	1	B-NP	CD	O	35	NMOD	0
30	,	,	I-NP	,	O	35	P	0
31	2	2	I-NP	CD	O	35	NMOD	0
32	,	,	O	,	O	35	P	0
33	and	and	O	CC	O	35	NMOD	0
34	3	3	B-NP	CD	O	35	NMOD	0
35	weeks	week	I-NP	NNS	O	28	PMOD	0
36	of	of	B-PP	IN	O	35	NMOD	0
37	treatment	treatment	B-NP	NN	O	36	PMOD	0
38	,	,	O	,	O	27	P	0
39	respectively	respectively	B-ADVP	RB	O	27	NMOD	0
40	.	.	O	.	O	3	P	0

1	Arterial	Arterial	B-NP	JJ	O	2	NMOD	0
2	pressure	pressure	I-NP	NN	O	5	NMOD	0
3	and	and	O	CC	O	5	NMOD	0
4	cardiac	cardiac	B-NP	JJ	O	5	NMOD	0
5	output	output	I-NP	NN	O	6	SUB	0
6	were	be	B-VP	VBD	O	0	ROOT	0
7	unchanged	unchanged	B-ADJP	JJ	O	6	PRD	0
8	.	.	O	.	O	6	P	0

1	Left	Leave	B-NP	VBN	O	5	NMOD	0
2	ventricular	ventricular	I-NP	JJ	O	5	NMOD	0
3	capillary	capillary	I-NP	JJ	O	5	NMOD	0
4	length	length	I-NP	NN	O	5	NMOD	0
5	density	density	I-NP	NN	O	12	SUB	0
6	(	(	O	(	O	11	DEP	0
7	mm/mm	mm/mm	B-NP	NN	O	11	DEP	0
8	(	(	O	(	O	10	DEP	0
9	3	3	B-NP	CD	O	10	DEP	0
10	)	)	O	)	O	7	NMOD	0
11	)	)	O	)	O	5	NMOD	0
12	increased	increase	B-VP	VBD	O	36	VMOD	17	increased
13	gradually	gradually	B-ADVP	RB	O	12	VMOD	0
14	with	with	B-PP	IN	O	12	VMOD	0
15	alinidine	alinidine	B-NP	NN	O	16	NMOD	0
16	administration	administration	I-NP	NN	O	14	PMOD	19	administration
17	;	;	O	:	O	36	P	0
18	a	a	B-NP	DT	O	21	NMOD	0
19	15	15	I-NP	CD	O	20	AMOD	0
20	%	%	I-NP	NN	O	21	NMOD	0
21	increase	increase	I-NP	NN	O	29	NMOD	17	increase
22	after	after	B-PP	IN	O	21	NMOD	0
23	2	2	B-NP	CD	O	24	NMOD	0
24	weeks	week	I-NP	NNS	O	22	PMOD	0
25	and	and	O	CC	O	29	NMOD	0
26	a	a	B-NP	DT	O	29	NMOD	0
27	40	40	I-NP	CD	O	28	AMOD	0
28	%	%	I-NP	NN	O	29	NMOD	0
29	increase	increase	I-NP	NN	O	36	SUB	17	increase
30	after	after	B-PP	IN	O	29	NMOD	0
31	3	3	B-NP	CD	O	32	NMOD	0
32	weeks	week	I-NP	NNS	O	30	PMOD	0
33	of	of	B-PP	IN	O	32	NMOD	0
34	alinidine	alinidine	B-NP	NN	O	35	NMOD	0
35	treatment	treatment	I-NP	NN	O	33	PMOD	19	treatment
36	were	be	B-VP	VBD	O	0	ROOT	0
37	documented	document	I-VP	VBN	O	36	VC	0
38	.	.	O	.	O	36	P	0

1	Left	Leave	B-NP	VBN	O	3	NMOD	0
2	ventricular	ventricular	I-NP	JJ	O	3	NMOD	0
3	weight	weight	I-NP	NN	O	10	NMOD	0
4	,	,	O	,	O	10	P	0
5	body	body	B-NP	NN	O	6	NMOD	0
6	weight	weight	I-NP	NN	O	10	NMOD	0
7	,	,	O	,	O	10	P	0
8	and	and	O	CC	O	10	NMOD	0
9	their	their	B-NP	PRP$	O	10	NMOD	0
10	ratio	ratio	I-NP	NN	O	11	SUB	0
11	were	be	B-VP	VBD	O	0	ROOT	0
12	not	not	I-VP	RB	O	11	VMOD	0
13	significantly	significantly	I-VP	RB	O	11	VMOD	0
14	altered	alter	I-VP	VBN	O	11	VC	0
15	by	by	B-PP	IN	O	14	VMOD	0
16	alinidine	alinidine	B-NP	NN	O	17	NMOD	0
17	treatment	treatment	I-NP	NN	O	15	PMOD	19	treatment
18	.	.	O	.	O	11	P	0

1	After	After	B-PP	IN	O	17	VMOD	0
2	1	1	B-NP	CD	O	3	NMOD	0
3	week	week	I-NP	NN	O	1	PMOD	0
4	of	of	B-PP	IN	O	3	NMOD	0
5	treatment	treatment	B-NP	NN	O	4	PMOD	0
6	,	,	O	,	O	17	P	0
7	before	before	B-PP	IN	O	17	VMOD	0
8	an	an	B-NP	DT	O	9	NMOD	0
9	increase	increase	I-NP	NN	O	7	PMOD	17	increase
10	in	in	B-PP	IN	O	9	NMOD	0
11	capillary	capillary	B-NP	JJ	O	13	NMOD	0
12	length	length	I-NP	NN	O	13	NMOD	0
13	density	density	I-NP	NN	O	10	PMOD	0
14	,	,	O	,	O	17	P	0
15	VEGF	VEGF	B-NP	NN	B-RNA	16	NMOD	0
16	mRNA	mRNA	I-NP	NN	I-RNA	17	SUB	0
17	increased	increase	B-VP	VBD	O	0	ROOT	17	increased
18	greater	great	B-ADJP	JJR	O	23	VMOD	0
19	than	than	B-PP	IN	O	18	AMOD	0
20	2-fold	2-fold	B-ADVP	RB	O	19	PMOD	0
21	and	and	O	CC	O	18	DEP	0
22	then	then	O	RB	O	23	VMOD	0
23	declined	decline	B-VP	VBD	O	17	VMOD	18	declined
24	to	to	B-PP	TO	O	23	VMOD	0
25	control	control	B-NP	NN	O	26	NMOD	0
26	levels	level	I-NP	NNS	O	24	PMOD	0
27	after	after	B-PP	IN	O	23	VMOD	0
28	3	3	B-NP	CD	O	29	NMOD	0
29	weeks	week	I-NP	NNS	O	27	PMOD	0
30	of	of	B-PP	IN	O	29	NMOD	0
31	treatment	treatment	B-NP	NN	O	30	PMOD	0
32	.	.	O	.	O	17	P	0

1	VEGF	VEGF	B-NP	NN	B-protein	2	NMOD	0
2	protein	protein	I-NP	NN	I-protein	3	SUB	0
3	was	be	B-VP	VBD	O	0	ROOT	0
4	higher	high	B-ADJP	JJR	O	3	PRD	0
5	in	in	B-PP	IN	O	4	AMOD	0
6	alinidine-treated	alinidine-treated	B-NP	JJ	O	7	NMOD	19	treated
7	rats	rat	I-NP	NNS	O	5	PMOD	0
8	than	than	B-PP	IN	O	4	AMOD	0
9	in	in	B-PP	IN	O	8	PMOD	0
10	controls	control	B-NP	NNS	O	9	PMOD	0
11	after	after	B-PP	IN	O	10	NMOD	0
12	2	2	B-NP	CD	O	13	NMOD	0
13	weeks	week	I-NP	NNS	O	11	PMOD	0
14	and	and	O	CC	O	4	DEP	0
15	increased	increase	B-VP	VBN	O	4	AMOD	17	increased
16	further	further	B-ADVP	RB	O	15	VMOD	0
17	after	after	B-PP	IN	O	15	VMOD	0
18	3	3	B-NP	CD	O	19	NMOD	0
19	weeks	week	I-NP	NNS	O	17	PMOD	0
20	of	of	B-PP	IN	O	19	NMOD	0
21	treatment	treatment	B-NP	NN	O	20	PMOD	0
22	.	.	O	.	O	3	P	0

1	Injection	Injection	B-NP	NN	O	10	SUB	19	Injection
2	of	of	B-PP	IN	O	1	NMOD	0
3	VEGF-neutralizing	VEGF-neutralizing	B-NP	JJ	B-protein	4	NMOD	0
4	antibodies	antibody	I-NP	NNS	I-protein	2	PMOD	0
5	over	over	B-PP	IN	O	1	NMOD	0
6	a	a	B-NP	DT	O	8	NMOD	0
7	2-week	2-week	I-NP	JJ	O	8	NMOD	0
8	period	period	I-NP	NN	O	5	PMOD	0
9	completely	completely	B-ADVP	RB	O	10	VMOD	0
10	blocked	block	B-VP	VBD	O	0	ROOT	18	blocked
11	alinidine-stimulated	alinidine-stimulated	B-NP	JJ	O	12	NMOD	17	stimulated
12	angiogenesis	angiogenesis	I-NP	NN	O	10	OBJ	3	angiogenesis
13	.	.	O	.	O	10	P	0

1	In	In	B-PP	IN	O	6	VMOD	0
2	contrast	contrast	B-NP	NN	O	1	PMOD	0
3	,	,	O	,	O	6	P	0
4	bFGF	bFGF	B-NP	NN	B-RNA	5	NMOD	0
5	mRNA	mRNA	I-NP	NN	I-RNA	6	SUB	0
6	was	be	B-VP	VBD	O	0	ROOT	0
7	not	not	I-VP	RB	O	6	VMOD	0
8	altered	alter	I-VP	VBN	O	6	VC	16	altered
9	by	by	B-PP	IN	O	8	VMOD	0
10	alinidine	alinidine	B-NP	NN	O	11	NMOD	0
11	treatment	treatment	I-NP	NN	O	9	PMOD	19	treatment
12	.	.	O	.	O	6	P	0

1	These	These	B-NP	DT	O	2	NMOD	0
2	data	datum	I-NP	NNS	O	3	SUB	0
3	suggest	suggest	B-VP	VBP	O	0	ROOT	0
4	that	that	B-SBAR	IN	O	3	VMOD	0
5	VEGF	VEGF	B-NP	NN	B-protein	6	SUB	0
6	plays	play	B-VP	VBZ	O	4	SBAR	0
7	a	a	B-NP	DT	O	9	NMOD	0
8	key	key	I-NP	JJ	O	9	NMOD	0
9	role	role	I-NP	NN	O	6	OBJ	0
10	in	in	B-PP	IN	O	6	VMOD	0
11	the	the	B-NP	DT	O	13	NMOD	0
12	angiogenic	angiogenic	I-NP	JJ	O	13	NMOD	3	angiogenic
13	response	response	I-NP	NN	O	10	PMOD	0
14	that	that	B-NP	WDT	O	13	NMOD	0
15	occurs	occur	B-VP	VBZ	O	14	SBAR	0
16	with	with	B-PP	IN	O	15	VMOD	0
17	chronic	chronic	B-NP	JJ	O	18	NMOD	0
18	bradycardia	bradycardia	I-NP	NN	O	16	PMOD	0
19	.	.	O	.	O	3	P	0

1	The	The	B-NP	DT	O	2	NMOD	0
2	mechanism	mechanism	I-NP	NN	O	7	SUB	0
3	underlying	underlie	B-VP	VBG	O	2	NMOD	0
4	this	this	B-NP	DT	O	6	NMOD	0
5	VEGF-associated	VEGF-associated	I-NP	JJ	O	6	NMOD	16	associated
6	angiogenesis	angiogenesis	I-NP	NN	O	3	OBJ	3	angiogenesis
7	may	may	B-VP	MD	O	0	ROOT	0
8	be	be	I-VP	VB	O	7	VC	0
9	an	an	B-NP	DT	O	10	NMOD	0
10	increase	increase	I-NP	NN	O	8	PRD	0
11	in	in	B-PP	IN	O	10	NMOD	0
12	stretch	stretch	B-NP	NN	O	11	PMOD	0
13	due	due	B-PP	JJ	O	14	PMOD	0
14	to	to	B-PP	TO	O	10	NMOD	0
15	enhanced	enhance	B-NP	VBN	O	17	NMOD	0
16	diastolic	diastolic	I-NP	JJ	O	17	NMOD	0
17	filling	filling	I-NP	NN	O	14	PMOD	0
18	.	.	O	.	O	7	P	0

